

Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand, Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra East, Mumbai-400051

Date: May 26, 2026

Dear Sir/Madam,

Sub: Outcome of board meeting held on today i.e., on May 26, 2026, in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC / INE002D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e., on Tuesday, May 26, 2026, at the Registered Office of the Company, which was commenced at 05:00 P.M. and concluded at 07:00 P.M., to have:

1. Considered, approved and taken on record the Audited Standalone & Consolidated financial results for the half year and year ended on March 31, 2026 along with Audit Report (Unmodified Opinion) and Declaration by the Company for the Audit Report with Unmodified Opinion;
2. Considered, approved & taken on record the Audited Standalone & Consolidated Financial Statement of the Company for the financial year ended on March 31, 2026 in accordance with the Companies Act, 2013;
3. Recommendation of final dividend of Rs. 0.20/- (Rupees Twenty paisa only) per Equity share having face value of Rs.10/- per equity share (i.e., 2.00 % of face value) for the financial year ended on March 31, 2026, subject to the approval of the members at the ensuing Annual General Meeting.

Final Dividend if approved by the members, will be paid/dispatched after the Annual General meeting.

4. Considered and approved all other business as per agenda circulated.

Kindly take the same on your record and oblige us.

Thanking you

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad
Encl.: A/a



Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand, Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451

Date: May 26, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir/Madam,

Sub: Submission of Audited Standalone & Consolidated Financial Result of the Company for the half year and year ended on March 31, 2026 along with Auditor Report (Unmodified Opinion) and Declaration for the Auditor's Report with Unmodified Report.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/ INE002D01012)

In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

1. Audited Standalone & Consolidated Financial Results for the half year and year ended on March 31, 2026.
2. Audited Statement of Standalone & Consolidated Asset & Liabilities for the year ended as at March 31, 2026.
3. Audited Standalone & Consolidated Cash Flow Statement for the year ended as at March 31, 2026.
4. Audit Report (unmodified opinion) on the Audited Financial Results.
5. Declaration by the Company (for the Auditor's report with unmodified opinion).

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252
Place: Ahmedabad

Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand, Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451

Date: May 26, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra East, Mumbai – 400051

Dear Sir/Ma'am,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/ INE002D01012)

In Compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO IGN/2016-17/001 dated May 25, 2016 and circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the Company, M/s. Keyur Shah & Co. Chartered Accountants, (FRN: 141173W) have issued an Audit Report with unmodified opinion on the Audited Standalone & Consolidated Financial Results of the Company for the half year and year ended March 31, 2026.

You are requested to take the same on records.

Thanking You,

Yours Faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252
Place: Ahmedabad



Independent Auditor's Report on consolidated audited half year and year ended financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**To The Board Of Directors Of
Sotac Pharmaceutical Limited**

Report on the audit of the Consolidated Financial Results Opinion

We have audited the accompanying Statement of Consolidated Financial Results of **Sotac Pharmaceutical Limited ("Parent")** and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), for the half year and year ended 31st March, 2026 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial results of the subsidiaries, the aforesaid consolidated financial results:

a. include the annual financial results of the following entities:


- Sotac Pharmaceutical Limited ("Parent")
- Sotac Healthcare Private Limited ("Subsidiary")
- Sotac Lifesciences Private Limited ("Subsidiary")
- Sotac Research Private Limited ("Subsidiary")

b. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations, as amended; and

c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated of net [profit/loss] other financial information of the Group for the half year and year ended 31st March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Consolidated Financial Results

These half year and year ended consolidated financial results have been prepared on the basis of the interim financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other financial information of the Group including in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group entities are responsible for assessing the ability of the Group entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group entities are responsible for overseeing the financial reporting process of the Group entities.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.



- Consider materiality as the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

We consider quantitative materiality and qualitative factors in-

- Planning the scope of our audit work and in evaluating the results of our work; and
- to evaluate the effect of any identified misstatements in the Consolidated Financial Results

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

Other Matters



The consolidated Financial Results include the audited Financial Results of 3 subsidiaries, whose interim Financial Statements/Financial Results/ financial information reflect Group's share of total assets of Rs. 6,753.28 Lakhs as at 31st March 2026, Group's share of total revenue of Rs. 3,942.60 Lakhs and Group's share of total net profit/(loss) after tax of Rs. 140.28 lakhs for the year ended 31st March 2026, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on interim financial statements/Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

The Statement includes the results for the half year ended 31st March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures, up to the first half of the year of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.



The Consolidated Annual Financial Results dealt with by this report have been prepared for the express purpose of filing with the Stock Exchanges. These results are based on, and should be read in conjunction with, the audited Consolidated Financial Results of the Company for the year ended 31st March 2026, on which we have issued an unmodified audit opinion.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W



Keyur Shah
Proprietor
M. No. 153774
UDIN: 26153774DNGWUX8739

Date: 26/05/2026
Place: Ahmedabad

SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110
Audited Consolidated Financial Result for the half year and year ended 31st March, 2026

Sr no.	Particulars	(Rs. in lakhs unless otherwise stated)					
		Half Year ended			Year ended		
		31st March, '26	30th September, '25	31st March, '25	31st March, '26	31st March, '25	
	Audited	Unaudited	Audited	Audited	Audited		
I)	Revenue From Operations	6,006.32	4,117.61	4,714.22	10,123.93	9,973.69	
II)	Other Income	22.57	12.13	44.60	34.70	114.65	
III)	Total Income (I + II)	6,028.89	4,129.74	4,758.82	10,158.63	10,088.34	
IV)	Expenses						
a)	Cost of Material Consumed	3,107.11	2,445.83	2,448.37	5,552.94	6,292.62	
b)	Purchase of Stock-in-Trade	908.60	70.23	61.45	978.83	133.21	
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	24.67	(105.47)	186.53	(80.80)	405.21	
d)	Employee Benefit Expenses	151.08	216.89	154.32	367.97	317.35	
e)	Finance Costs	225.13	187.70	156.51	412.83	257.87	
f)	Depreciation and Amortisation Expense	270.56	269.96	235.07	540.52	383.52	
g)	Other Expenses	807.29	709.20	656.68	1,516.49	1,186.55	
	Total Expenses (IV)	5,494.44	3,794.34	3,898.93	9,288.78	8,976.33	
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III - IV)	534.45	335.40	859.89	869.85	1,112.01	
VI)	Exceptional/Prior Period Items	(0.00)	(0.22)	-	(0.22)	(0.04)	
VII)	Profit/(loss) from ordinary activities before Extraordinary Items and Tax (V-VI)	534.45	335.18	859.89	869.63	1,111.97	
VIII)	Extraordinary Items	-	-	-	-	-	
IX)	Profit Before Tax (VII-VIII)	534.45	335.18	859.89	869.63	1,111.97	
X)	Tax Expense						
a)	Current Tax	108.62	83.94	94.04	192.56	171.85	
b)	Deferred Tax	39.95	(7.67)	15.16	32.28	12.58	
c)	Income Tax Prior Period	15.46	-	-	15.46	-	
	Total Tax Expenses (X)	164.03	76.27	109.20	240.30	184.43	
XI)	Profit (Loss) for the period from continuing operations (IX-X)	370.42	258.91	750.69	629.33	927.54	
XII)	Profit/(loss) from discontinuing operations	-	-	-	-	-	
XIII)	Tax expense of discontinuing operations	-	-	-	-	-	
XIV)	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	
XV)	Profit / (Loss) For The Period/Year before Minorities (XI+XIV)	370.42	258.91	750.69	629.33	927.54	
XVI)	Less: Share of Minorities In Subsidiary Companies (Loss)/Profit	38.34	14.32	139.27	52.66	124.87	
XVII)	Profit/(Loss) for the period	332.08	244.59	611.42	576.67	802.67	
XVIII)	Paidup Equity Share Capital (Face value Rs 10 each)	1,105.00	1,105.00	1,105.00	1,105.00	1,105.00	
XIX)	Reserve & Surplus (Excluding Revaluation Reserve)	-	-	-	4,463.18	4,220.19	
XX)	Earnings Per Equity Share-Basic/Diluted						
	Basic /Diluted earnings per share (In INR) (not annualised, for the Half year ended)	3.01	2.21	5.53	5.22	7.26	

Notes:
[1] The consolidated Audited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable

[2] The above consolidated audited financial results half year and year ended 31st March, 2026 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements)

Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on 26th May, 2026.

[3] As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.

[4] The figures for the half year ended 31st March, 2026 are the Balancing figures between the audited figures in respect of full financial year and unaudited figures in respect of first half of the financial year 25-26.

[5] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.

[6] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.

[7] The Board of Directors at its meeting held on 26th May, 2026 proposed a dividend of Rs. 0.20 Per Equity share subject to the approval of the shareholders in the upcoming Annual General Meeting.

[8] The Status of investor's complaints during the half year ended on 31st March, 2026 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

[8] List of the Entities Consolidated in the Statement:

Name of the Subsidiaries Companies	% of Holding as on 31st March, 2026	Voting Power Either Directly or Indirectly through Subsidiaries
Sotac Healthcare Private Limited	71.00	Directly
Sotac Research Private Limited	100.00	Directly
Sotac Lifesciences Private Limited	55.77	Directly

For, Sotac Pharmaceuticals Limited


Sharad Patel
DIN:07252252
Chairman & Managing Director



Place : Ahmedabad
Date : 26th May, '26

SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451
Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110
Audited Consolidated Balance Sheet As At 31st March, 2026

Particulars	Rs. In Lakhs (unless otherwise stated)	
	As at	As at
	31st March, '26	31st March, '25
	Audited	Audited
I. EQUITY AND LIABILITIES		
Share Holder's Fund		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves and Surplus	4,782.48	4,220.19
	5,887.48	5,325.19
Share Application Money Pending Allotment	-	-
Minority Interest	569.70	517.04
Non-Current Liabilities		
(a) Long-Term Borrowings	1,038.78	1,419.41
(b) Deferred Tax Liabilities (Net)	-	-
(c) Long Term Provisions	15.10	16.28
Total Non-Current Liabilities	1,053.88	1,435.69
Current Liabilities		
(a) Short-Term Borrowings	2,720.90	2,950.52
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	1,932.38	666.99
ii) Total outstanding dues other than micro enterprise and small enterprise	786.77	1,227.44
(c) Other Current Liabilities	224.96	156.20
(d) Short-Term Provisions	170.97	153.75
Total Current Liabilities	5,835.98	5,154.90
TOTAL EQUITY & LIABILITIES	13,347.04	12,432.82
II.ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	4,577.40	4,676.77
(ii) Intangible Assets	198.70	1.85
(iii) Capital work In -Progress	170.74	20.35
(iv) Goodwill on Consolidation	190.34	190.34
(b) Non-Current Investments	291.63	378.19
(c) Deferred Tax Assets (Net)	97.81	130.09
(d) Long Term Loans and Advances	52.49	52.49
Total Non-Current Assets	5,579.11	5,450.08
Current Assets		
(a) Inventories	2,707.73	2,026.09
(b) Trade Receivables	3,295.04	3,411.22
(c) Cash and Cash Equivalents	117.80	156.39
(d) Short-Term Loans And Advances	33.70	52.17
(e) Other Current Assets	1,613.66	1,336.87
Total Current Assets	7,767.93	6,982.74
TOTAL ASSETS	13,347.04	12,432.82

For, Sotac Pharmaceuticals Limited



Sharad Patel

Sharad Patel
DIN:07252252
Chairman & Managing Director

Place: Ahmedabad
Date : 26th May, '26

SOTAC PHARMACEUTICALS LIMITED

CIN : L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Opp. Teva Pharma, Sanand GIDC-II, Sanand, Gujarat, Ahmedabad-382110

Audited Consolidated Cashflow Statement For The Year Ended 31st March, 2026

Particulars	Rs. In Lakhs (unless otherwise stated)	
	For the year ended	For the year ended
	31st March, 2026	31st March, 2025
	Audited	Audited
Cash Flow from Operating Activities		
Net Profit before tax paid	869.63	1,111.96
Adjustments for :		
Depreciation and amortization	540.55	383.52
Interest income	(3.37)	(15.17)
Dividend Income	(1.74)	(1.06)
Profit on Sale of Fixed Assets	(6.96)	
Provision for Gratuity	0.19	4.38
Finance Cost	412.83	257.87
Adjustment Related to IPO Expense and Deffered Government Grants	(3.33)	(3.40)
Operating profit before working capital changes (a)	1,807.80	1,738.10
Adjustment for Changes in Working Capital :		
Increase / (Decrease) in Trade Payables	824.72	(994.93)
Increase / (Decrease) in Other Current Liabilities	68.76	23.05
Increase / (Decrease) in Short term Provisions	17.22	(15.35)
(Increase) / Decrease in Inventories	(681.64)	(225.09)
(Increase) / Decrease in Trade Receivables	116.18	(782.45)
(Increase) / Decrease in Short Term Loans and Advances	18.47	(35.37)
(Increase) / Decrease in Other Current Assets	(276.79)	(60.68)
Operating profit after working capital changes (b)	86.92	(2,090.82)
Cash generated from Operations (a+b)	1,894.72	(352.72)
Taxes paid (net of refund)	(208.02)	(80.46)
Net Cash generated from Operations (A)	1,686.70	(433.18)
Cash Flow from Investing Activities		
Addition in Property, Plant and Equipments and Intangible Assets	(639.04)	(1,701.62)
Disposals Of Property, Plant and Equipments And Intangible Assets	8.00	0.26
(Increase) / Decrease in Capital Work in Progress	(150.39)	492.08
(Increase) / Decrease in of Loans and advances	-	0.03
(Increase) / Decrease In Non Current Investments	86.56	(168.57)
Interest income	3.37	15.17
Dividend Income	1.74	1.06
Net Cash generated / (used) in Investing Activities (B)	(689.76)	(1,361.59)



SOTAC PHARMACEUTICALS LIMITED

CIN : L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Opp. Teva Pharma, Sanand GIDC-II, Sanand, Gujarat, Ahmedabad-382110

Audited Consolidated Cashflow Statement For The Year Ended 31st March, 2026

Particulars	Rs. In Lakhs (unless otherwise stated)	
	For the year ended	For the year ended
	31st March, 2026	31st March, 2025
	Audited	Audited
Cash Flow from Financing Activities		
Issued Share against Share Application Money received		-
Proceeds from Issue of New Equity Share_Securities Premium		-
Changes In Minority Interest	-	(15.00)
Increase / (Decrease) in Long Term provisions	(1.37)	(1.81)
Repayment of Long Term Borrowings	(726.36)	(1,022.69)
Proceeds from Long Term Borrowings	345.70	1,229.00
Increase / (Decrease) of Short term Borrowings	(229.62)	1,677.75
Finance Cost	(412.83)	(257.87)
Dividend Paid	(11.05)	-
Net Cash generated / (used) in Financing Activities (C)	(1,035.53)	1,609.38
Net Increase in Cash and Cash Equivalents (A+B+C)	(38.59)	(185.39)
Cash and Cash Equivalents as on 1st April, 2025	156.39	341.78
Cash and Cash Equivalents as on 31st March, 2026	117.80	156.39

Notes :

1. The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.

For, Sotac Pharmaceuticals Limited



Sharad Patel

Sharad Patel
DIN:07252252
Chairman & Managing Director

Place: Ahmedabad
Date : 26th May, '26



Independent Auditor's Report on Audited standalone half year and year ended Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To The Board Of Directors Of
Sotac Pharmaceutical Limited**

Report on the audit of the Standalone Financial Results Opinion

We have audited the accompanying standalone half year and year financial results of "Sotac Pharmaceutical Limited (the company)" for the half year and year ended 31st March 2026, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2026, and Profit for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

This financial result has been prepared on the basis of the annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Accounting Standard prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.
- Consider materiality as the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

We consider quantitative materiality and qualitative factors in-

- Planning the scope of our audit work and in evaluating the results of our work; and
- to evaluate the effect of any identified misstatements in the Standalone Financial Results

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters:

The Standalone Annual Financial Results dealt with by this report have been prepared for the express purpose of filing with the Stock Exchanges. These results are based on, and should be read in conjunction with, the audited Standalone Financial Results of the Company for the year ended 31st March 2026, on which we have issued an unmodified audit opinion.

The Statement includes the results for the half year ended 31st March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures, up to the first half of the year of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W



Keyur Shah
Proprietor
M. No. 153774
UDIN: -26153774PYTYLJ7801

Date: - 26/05/2026
Place: - Ahmedabad


SOTAC PHARMACEUTICALS LIMITED
CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110
Audited Standalone Financial Result for the half year and year ended 31st March, 2026

Sr no.	Particulars	(INR in Lakhs unless otherwise Specified)					
		Half year ended			Year ended		
		31st March, 2026 Audited	30th September, 2025 Unaudited	31st March, 2025 Audited	31st March, 2026 Audited	31st March, 2025 Audited	
I)	Revenue From Operations	4,707.63	2,480.32	3,177.00	7,187.95	6,238.42	
II)	Other Income	99.85	109.99	145.25	209.84	237.50	
III)	Total Income (I + II)	4,807.48	2,590.31	3,322.25	7,397.79	6,475.92	
IV)	Expenses						
a)	Cost of Material Consumed	2,287.27	1,462.45	1,940.43	3,749.72	3,943.38	
b)	Purchase of Stock-in-Trade	1,219.95	70.23	61.45	1,290.18	133.21	
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	(3.70)	(66.46)	183.04	(70.16)	316.25	
d)	Employee Benefit Expenses	140.24	112.02	78.97	252.26	176.94	
e)	Finance Costs	77.90	101.38	67.13	179.28	116.71	
f)	Depreciation and Amortisation Expense	129.02	121.12	127.42	250.14	247.40	
g)	Other Expenses	576.73	476.97	506.64	1,053.70	900.58	
	Total Expenses (IV)	4,427.41	2,277.71	2,965.08	6,705.12	5,834.47	
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III - IV)	380.07	312.60	357.17	692.67	641.45	
VI)	Exceptional/Prior Period Items	-	(0.22)	-	(0.22)	(0.04)	
VII)	Profit/(Loss) from ordinary activities Before Extraordinary Items & Tax (V - VI)	380.07	312.38	357.17	692.45	641.41	
VIII)	Extraordinary Items	-	-	-	-	-	
IX)	Profit Before Tax (VII-VIII)	380.07	312.38	357.17	692.45	641.41	
X)	Tax Expense						
a)	Current Tax	103.86	83.94	95.37	187.80	171.47	
b)	Deferred Tax	2.89	(4.78)	(3.73)	(1.89)	(7.23)	
c)	Income Tax Excess Provisions Related to Earlier Years	14.72	-	-	14.72	-	
	Total Tax Expense	121.47	79.16	91.64	200.63	164.24	
XI)	Profit (Loss) for the period from continuing operations (IX-X)	258.60	233.22	265.53	491.82	477.17	
XII)	Profit/(loss) from discontinuing operations	-	-	-	-	-	
XIII)	Tax expense of discontinuing operations	-	-	-	-	-	
XIV)	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	
XV)	Profit / (Loss) For The Period/Year (XI+XIV)	258.60	233.22	265.53	491.82	477.17	
XVI)	Paid up Equity Share Capital (Face value Rs 10 each)	1105.00	1105.00	1105.00	1105.00	1105.00	
XVII)	Reserve & Surplus (Excluding Revaluation Reserve)				4677.04	4197.94	
XVIII)	Earnings Per Equity Share-Basic/Diluted						
	Basic /Diluted earnings per share (In INR) (not annualised, for the Half year ended)	2.21	2.11	2.40	4.45	4.32	

- Notes:**
- The above standalone financial results for the Half Year Ended and Financial Year Ended on 31st March, 2026 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 26th May, 2026.
 - The standalone audited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.
 - The figures for the Half year ended 31st March, 2026 are the Balancing figures between the audited figures in respect of full financial year and the unaudited figures in respect of first Half of the Financial year 25-26.
 - Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.
 - In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above results have been reviewed by the Statutory Auditors of the Company.
 - Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment, hence segment reporting is not applicable to Company.
 - The Board of Directors at its meeting held on 26th May, 2026 proposed a dividend of Rs. 0.20 Per Equity share subject to the approval of the shareholders in the upcoming Annual General Meeting.
 - The Status of investor's complaints during the Year ended on 31st March, 2026 as under:-

Complaints pending at the beginning of the period	Nill
Complaints received during the period	Nill
Complaints disposed during the period	Nill
Complaints resolved at the end of the period	Nill



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
Sharad Patel
Chairman & Managing Director
DIN:07252252

Place : Ahmedabad
Date : 26th May, 2026


SOTAC PHARMACEUTICALS LIMITED

CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Audited Standalone Balance Sheet as at 31st March, 2026

Particulars	(INR in lakhs, unless otherwise stated)	
	As at	As at
	31st March, 2026	31st March, 2025
	Audited	Audited
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,105.00	1,105.00
(b) Reserves And Surplus	4,677.04	4,197.94
(c) Money Received Against Share Warrants	-	-
	5,782.04	5,302.94
(2) Share Application Money Pending Allotment	-	-
(3) Non-Current Liabilities		
(a) Long-Term Borrowings	156.39	563.48
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	9.32	13.69
Total Non-Current Liabilities	165.71	577.17
(4) Current Liabilities		
(a) Short-Term Borrowings	1,052.52	1,449.30
(b) Trade Payable		
i) Total outstanding dues of micro enterprise and small enterprise	1,619.48	449.76
ii) Total outstanding dues other than micro enterprise and small	506.81	483.39
(c) Other Current Liabilities	199.38	145.51
(d) Short-Term Provisions	134.83	121.34
Total Current Liabilities	3,513.02	2,649.30
TOTAL EQUITY & LIABILITIES	9,460.77	8,529.41
ii. ASSETS		
(1) Non-Current Assets		
(a) Property, Plant & Equipment & Intangible Assets		
(i) Property, Plant & Equipment	1,675.81	1,664.29
(ii) Intangible Assets	131.99	1.85
(iii) Capital Work In -Progress	170.74	20.35
(b) Non-Current Investments	1,218.41	1,333.40
(c) Deferred Tax Assets (Net)	21.74	19.85
Total Non-Current Assets	3,218.69	3,039.74



SOTAC PHARMACEUTICALS LIMITED

CIN:L24230GJ2015PLC085451

Plot No PF-21 & PF-22/A,Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Audited Standalone Balance Sheet as at 31st March, 2026

Particulars	(INR in lakhs, unless otherwise stated)	
	As at 31st March, 2026	As at 31st March, 2025
(2) Current Assets		
(a) Current investments	-	-
(b) Inventories	1,528.44	1,017.51
(c) Trade Receivables	2,879.05	2,468.09
(d) Cash and Cash Equivalents	33.91	44.61
(e) Short-Term Loans And Advances	869.58	1,232.58
(f) Other Current Assets	931.10	726.88
Total Current Assets	6,242.08	5,489.67
TOTAL ASSETS	9,460.77	8,529.41

For & on behalf of Sotac Pharmaceuticals Limited



Sharad Patel
Chairman & Managing Director
DIN:07252252

Place: Ahmedabad
Date : 26th May, 2026

SOTAC PHARMACEUTICALS LIMITED

Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110

Audited Cash Flow Statement for the Year Ended 31st March, 2026

Particulars	(INR in lakhs, unless otherwise stated)	
	For The Year Ended 31st March, 2026	For The Year Ended 31st March, 2025
	Audited	Audited
Cash Flow from Operating Activities		
Net Profit Before Tax Paid	692.45	641.41
Adjustments for :		
Depreciation And Amortization	250.14	247.40
Interest Income	(188.71)	(156.78)
Dividend income	(1.39)	
Profit on Sale of Fixed Assets	(6.96)	
Finance Cost	179.28	116.71
Provision for Gratuity	(3.05)	2.95
Adjustment Related to IPO Expense and Deffered Government Grants	(1.67)	(1.67)
Operating Profit Before Working Capital Changes (a)	920.09	850.02
Adjustment For Changes In Working Capital :		
Increase / (Decrease) In Trade Payables	1,193.14	(541.83)
Increase / (Decrease) In Other Current Liabilities	53.87	45.19
Increase / (Decrease) In Short term Provisions	0.78	(46.50)
(Increase) / Decrease In Inventories	(510.93)	84.82
(Increase) / Decrease In Trade Receivables	(410.96)	(266.86)
(Increase) / Decrease In Short Term Loans and Advances	363.00	(515.78)
(Increase) / Decrease In Other Current Assets	(204.22)	(136.80)
(b)	484.68	(1,377.76)
Cash Generated From Operations (a + b)	1,404.77	(527.74)
Taxes Paid (Net Of Refund)	(189.81)	(80.46)
Net Cash Generated From Operations (A)	1,214.96	(608.20)
Cash Flow From Investing Activities		
Addition In Propery, Plant and Equipments And Intagible Assets	(392.84)	(147.08)
Disposals Of Propery, Plant and Equipments And Intagible Assets	8.00	0.26
Addition In Capital Work In Progress	(150.39)	(15.58)
(Increase) / Decrease In Non Current Investment	114.99	(183.57)
Interest Income	188.71	156.78
Dividend income	1.39	
Net Cash Generated / (Used) in Investing Activities (B)	(230.14)	(189.19)



SOTAC PHARMACEUTICALS LIMITED
Plot No PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Ahmedabad-382110
Audited Cash Flow Statement for the Year Ended 31st March, 2026

Particulars	(INR in lakhs, unless otherwise stated)	
	For The Year Ended 31st March, 2026	For The Year Ended 31st March, 2025
	Audited	Audited
Cash Flow From Financing Activities		
Repayment of Long Term Borrowings	(452.79)	(861.00)
Proceeds From Long Term Borrowings	45.70	983.54
Increase / (Decrease) In long term Provisions	(1.32)	(1.63)
Increase / (Decrease) In of Short term Borrowings	(396.78)	773.63
Finance Cost	(179.28)	(116.71)
Dividend Paid On Equity Shares	(11.05)	
Net Cash Generated / (Used) In Financing Activities	(995.52)	777.83
Net Increase In Cash And Cash Equivalentts	(10.70)	(19.56)
Cash And Cash Equivalentts beginning of the Year	44.61	64.17
Cash and cash equivalent at end of year	33.91	44.61

Notes :

1. The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel

Sharad Patel
Chairman & Managing Director
Din No-07252252

Place: Ahmedabad
Date : 26th May, 2026